Detalles de la búsqueda
1.
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
J Eur Acad Dermatol Venereol
; 37(10): 2056-2066, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37335885
2.
Reactivity of allyl methyl sulphide, the in-vitro metabolite of garlic, with some amino acids and with phospholipid involved in viral infections.
J Biomol Struct Dyn
; 40(1): 565-571, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32835626
3.
Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life.
J Dermatolog Treat
; 33(5): 2605-2613, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35763326
4.
Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies.
Dermatitis
; 32(1S): S39-S44, 2021 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34175862
5.
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Am J Clin Dermatol
; 22(5): 693-707, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34406619
6.
Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Am J Clin Dermatol
; 22(6): 905, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34642878
Resultados
1 -
6
de 6
1
Próxima >
>>